Highlight of the presentation by Joseph Buxbaum PhD, Professor of Psychiatry; Director, Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, at Synchrony 2020 Symposia

Dr Buxbaum discussed development of novel treatments for autism based on the knowledge gleaned from rare genetic disorders. He explained how genetics, therefore, provides a mechanism to stratify ASD subjects and to develop precision medicine approaches.

This talk was part of first day of Synchrony 2020 Online Symposium - 'From Bench to Biopharma', organised by the The BRAIN Foundation in partnership with UC Davis MIND Institute and CalTech.

For more Synchrony 2020 talks and highlights: https://www.youtube.com/playlist?list=PLDtO9h17tcWcRGZHOgtNG9YMJ7BJkO6VR

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

Synchrony https://synchronysymposium.com/ is the first and only international symposium on translational research in #autism, that brings together academia, #biotech, pharmaceutical companies and #venture partners from around the world with the mission to improve health and quality of life of people with #autismspectrumdisorder.

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

The BRAIN Foundation https://brainfoundation.org/ is a 501c(3) non-profit. The founders of BRAIN envision a world where every child and adult on the autism spectrum is healthy, participates fully in education and employment, and has a better quality of life. It aims to catalyze research that results in evidence-based interventions for the disabilities associated with autism, and also results in better medical standard of care.

To accomplish this, it funds impactful research through #philanthropy and our network of partners in the venture, corporate, and grassroots community.